The Federal Trade Commission Tuesday said it had approved an amended final order settling charges that Teva Pharmaceutical Industries Ltd.'s acquisition of Cephalon Inc. would have been anticompetitive in the markets for several current and future generic drugs.
Teva, with operations in North Wales, Pa., completed the $6.8 billion purchase in October, shortly after the FTC approved the deal on a conditional basis.
As part of the settlement, Teva must sell the rights and assets related to generic drugs Actiq and Amrix to Par Pharmaceuticals, Inc.
